Skip to main content
. 2014 Feb 7;35(6):1292–1300. doi: 10.1093/carcin/bgu041

Fig. 3.

Fig. 3.

Testing of 20-gene rEASP signature as a predictor of patient survival in lung cancer: lung cancer patients from Bild’s, Okayama’s and Raponi’s data sets were stratified using 20-gene rEASP signature into low-, medium- and high-risk groups based on survival analysis by RSF model built on Shedden 442 training set. Shown are the Kaplan–Meir survival curves based on mortality. The log-rank P values compare the groups stratified by EASP signature.